Conclusion:
T2T gave more favourable trajectories of change in DAS28 and HAQ, but adverse HAQ trajectory was more likely in females with greater fatigue, suggesting such patients would benefit from interventions to improve function as well as reduce inflammation.
SIGNIFICANCE AND INNOVATIONS
 Disability can persist despite suppression of inflammation in RA  This phenomenon is more likely in females, older patients, those with greater body mass index and those with greater baseline fatigue Disability is a well recognised adverse outcome in rheumatoid arthritis (RA), which impacts upon the health and wellbeing of individuals with the disease [1] and results in significant direct and indirect (that is, incurred due to time out of work) health care costs [2] [3] [4] . Modern RA management largely targets suppression of inflammation, a phenomenon undoubtedly related to substantial advances in pharmacological therapies over recent decades. In 2010, there was a step-change in RA management with the introduction of the treat to target (T2T) approach, which advocated frequent clinical review to achieve remission or low disease activity [5] .
This approach is effective for reducing disease activity and achieving remission more rapidly [6, 7] . However, studies investigating the impact of T2T on functional outcome, measured by the Health Assessment Questionnaire (HAQ), have given different results. The open-label Computer Assisted Management in Early RA (CAMERA) study found no difference in the area-under the curve of HAQ over two years between groups treated to target and those receiving conventional step-up therapy [8] . Similarly, a randomized controlled trial from the British Rheumatoid Outcome Study Group (BROSG) compared aggressive RA therapy to symptomatic therapy, with HAQ as the primary outcome, and found that there was no significant difference in HAQ between the two treatment groups after 3 years [9] . Importantly, this study enrolled patients with established RA, whereas others have explored change in disability in early RA.
Greater improvement in HAQ was demonstrated in a T2T, compared to standard care group in the Dutch RA monitoring study (decrease in HAQ of 0.5, compared to 0.3 over 1 year), although HAQ was not the primary outcome investigated [10] .
Similarly, reduction in HAQ after 12 months was greater in the French 'GUEPARD' study, where treatment was targeted at low disease activity (defined as disease activity from counts of 28 joints, DAS28<3.2), compared to the French national observational cohort of early inflammatory arthritis 'ESPOIR' where cases received standard care. The median change in HAQ was -0.94 (95% confidence interval
[CI]1.15 to -0.72) in GUEPARD compared to -0.68 (-0.81 to -0.55) in ESPOIR [11] .
In the same study, DAS28 remission with no radiographic progression and HAQ<0.5 was more likely in the T2T group (32.3% of cases) than the standard care group
It is evident that management using T2T approaches improves DAS28 and achieves remission more rapidly, but it is not clear whether T2T has lead to equivalent advances in improving functional outcomes. Here, we compare the changes in DAS28 and HAQ over the first 2 years in early RA in two observational cohorts: the first, established in 2002, captured data on patients treated according to a traditional 'step-up' approach, whilst in the second cohort, initiated in 2009, patients were treated according to T2T. To our knowledge, this study is the first application of modern statistical techniques to evaluate the impact of T2T on functional outcome.
We have used latent growth curve and latent class growth analyses (LCGA), in order to make use of all available DAS28 and HAQ records in our datasets. These methods are preferable to comparing 2 year change in DAS28 or HAQ, or average change over time, because fluctuations in disease activity and disability between the two time-points can be accounted for. Thus, a comprehensive assessment of change in disability was obtained and compared between the two cohorts.
PATIENTS AND METHODS
Data from patients recruited to Yorkshire Early Arthritis Register (YEAR, described previously [12] ) between 2002-2009 were used. Briefly, YEAR recruited subjects aged over 18 with a consultant-made diagnosis of RA from 14 hospitals within Yorkshire, UK. They were enrolled within 24 months of RA symptom onset and followed for 2 years. Management was guided by a treatment protocol using a 'stepup' approach with synthetic disease modifying anti-rheumatic drugs (DMARD) and methotrexate (MTX) as the first line agent. Although deviations from the protocol occurred at the discretion of the treating rheumatologist, an initial dose of 7.5mg of MTX at the baseline assessment was suggested, escalating after 4 weeks to 10mg for 4 weeks, then 15mg for 4 weeks. Then it was increased to 20mg at the 3 month visit if disease was active at that point and the addition of Sulphasalazine (SSA) was recommended at 6 months if the response was inadequate. Active disease was judged by the treating physician and not specifically guided by composite measures of disease activity. After 9 months, the protocol recommended adding hydroxychloroquine or parenteral MTX. After 12 months, the protocol suggested switching to or adding Leflunomide. The treatment protocol is summarised in supplementary online Table 1 . The Inflammatory Arthritis CONtinuum study (IACON) recruited cases aged over 18 with early inflammatory arthritis, at their first presentation to Leeds Teaching Hospitals NHS Trust, between 2010-2014. For the present study, IACON cases were selected if 2010 ACR/EUALR criteria for RA [13] were met at baseline or during follow up. There was no agreed treatment protocol; however, patients were treated in a single centre according to contemporary best YEAR data collection, so were acquired retrospectively, using samples stored at minus 20°C and laboratory methods described previously [15] .
Statistical analysis
The cohorts were described using means and standard deviations for continuous normally distributed variables, median and interquartile range for non-normally distributed variables, and percentages for categorical data. As HAQ is an ordinal variable, it was transformed using Rasch analysis (discussed by Tennant and Conaghan [16] ) to facilitate its use as an interval variable in statistical models. Multinomial logistic regression was used to identify baseline determinants of trajectory group. Analyses were carried out using Mplus version 6.1. Muthèn and Muthèn, Los Angeles, CA [17] . Missing data were handled using maximum likelihood estimation.
Three post-hoc analyses
There were fewer trajectories of change in HAQ in IACON than YEAR, with the loss of the most adverse (high stable) trajectory in IACON. We therefore investigated whether this result occurred simply because there were fewer IACON cases, by repeating the LCGA using all YEAR and IACON data in the same model. Then, to test whether cases from the T2T group were more likely to be classified in either trajectory, logistic regression was used in a model that included T2T as a predictor of trajectory class (together with interaction terms between T2T and all other independent variables to account for possible differences in effects of predictors on trajectory group between the two cohorts). We also tested whether the preferable outcome in IACON could have occurred because this group included patients not meeting RA criteria at baseline, by excluding these cases and repeating the LCGA. 
RESULTS

Cohort characteristics
The analysis included 725 patients recruited to YEAR (traditional treatment) and 384 IACON (T2T) cases. hydroxychloroquine was also more common in IACON patients, and this may be because IACON cases were at an earlier stage of RA, with less inflammation and therefore less aggressive therapy was indicated for these patients.
Mean change in DAS28 and HAQ over time in YEAR and IACON
Details growth curve models fit are provided in supplementary online Table 5 . The latent growth curve models showed that mean DAS28 was lower throughout follow up in the T2T group (IACON) than the traditional therapy group (YEAR) and that a greater proportion of overall change in DAS28 occurred by 6 months in the T2T group: 0.86 of overall change (95% CI 0.71, 1.00) compared to 0.62 (0.34, 0.69). However, the difference in mean DAS28 between the two groups was less marked after 2 years, as shown in supplementary Figure S3 . Although HAQ was initially lower in IACON, the difference between mean HAQ in YEAR and IACON at 12 months was minimal, and mean HAQ was slightly higher in IACON at 2 years ( Figure   2 ). The growth curve models represent mean change of the whole cohort and considerable variation between individuals is likely; therefore, distinct trajectories of change in DAS28 and HAQ were sought using LCGA.
Trajectories of change in DAS28 and HAQ
Details of fit of models with successive numbers of trajectories are provided in supplementary online Table 7 . The fit of the growth curve model of change in DAS28 in IACON was not improved by adding trajectories. However, in YEAR, there were two trajectories of change in DAS28, as shown in Figure 3 . These were interpreted to represent high stable and low reducing DAS28, based on the observed trends over time. There were 2 trajectories of change in HAQ in IACON (moderate reducing and low reducing) and 3 in YEAR (high stable, moderate reducing and low reducing), which are shown in Figure 4 . The most disabled group, with HAQ of about 2 throughout follow-up, was described by the high stable trajectory; the low reducing HAQ trajectory was the most favorable, with lowest HAQ throughout followup and the moderate reducing trajectory described a group with average HAQ between these two.
Predictors of HAQ trajectory
Compared to low reducing trajectories, individuals were more likely to be classified into moderate reducing (YEAR and IACON) or high stable (YEAR only) trajectories if they were female, older, or had greater baseline fatigue (odds ratios [OR] are given in Table 2 ). Higher BMI was also statistically significantly associated with the high stable trajectory in YEAR and moderate reducing trajectory in IACON. The association with BMI almost reached statistical significance for the moderate reducing trajectory in YEAR. Smoking (ever versus never) was associated with increased odds of the moderate reducing, compared to low reducing trajectory in YEAR, but was not a significant predictor in IACON. The effects of current and previous versus never smoking were tested separately, and again, smoking did not predict IACON HAQ trajectory, or high stable versus low reducing trajectories in YEAR. However, the significant effect of smoking on the moderate reducing trajectory described in Table 2 was present again, whereby past smokers were more likely than never-smokers to be classified in the moderate reducing compared to low reducing trajectory (OR 1.64, 95% CI 1.08, 2.51, p=0.022). Current smokers were not significantly more likely than never-smokers to be in the moderate reducing than the low reducing trajectory (OR 1.48, 95% confidence interval, CI, 0.94, 2.34, p=0.095).
DISCUSSION
In both cohorts, more favourable 'low reducing' trajectories of HAQ were identified, representing 44% and 34% of YEAR and IACON, respectively. The remainder of cases were classified by moderate reducing trajectories, and a high stable trajectory in YEAR. Although the absence of the high stable trajectory in IACON suggests a better outcome compared to YEAR, most (66%) IACON cases followed a moderate reducing trajectory in which mean HAQ score was 1.45 at baseline and 1.22 at 2 years, indicating ongoing disability for most of the cohort, despite treatment targeted at disease activity.
We considered whether there was no high stable trajectory in IACON because there were fewer cases in this group than in YEAR. In a post-hoc analysis whereby YEAR and IACON data were analyzed together there were only 2 trajectories of HAQ (results available in supplementary online Table 8 ). Therefore, the two trajectory solution to the model of HAQ change in IACON was not due to the lower number of cases in IACON. We also considered whether the results could have arisen because IACON included 47 cases who did not meet RA criteria at the initial visit and conducted a further post-hoc analysis of the 337 cases meeting RA criteria at baseline. This gave similar results (shown in online supplementary Table 9 ), so the findings were not significantly affected by including cases who did not initially meet RA criteria. Furthermore, a comparison of trajectories of DAS28 between the two cohorts suggests an alternative explanation for the absence of the high stable HAQ trajectory in IACON. Two trajectories of change in DAS28 were identified in YEAR and 23% of cases followed a high stable trajectory with persistently elevated DAS28 of >4.5 (shown in Figure 3 ). However, there was no high stable DAS28 trajectory in IACON. Therefore, DAS28 over 2 years was more favorable for IACON than YEAR cases, consistent with previous evidence of improved control of disease activity with T2T. Lower disease activity over 2 years in IACON could explain a more favorable HAQ change in this group, that is, the absence of the high stable HAQ trajectory.
We investigated baseline predictors of adverse HAQ outcome and found that female gender, older age, higher BMI, and higher fatigue were associated with the high stable HAQ trajectory in YEAR and the moderate reducing trajectory in IACON. An association between female gender and adverse HAQ outcome has been noted before [19] [20] [21] [22] [23] . Similarly, morbid obesity has also been associated with worse HAQ [24] and it is possible that the inflammatory nature of adipose tissue contributes to inflammation in RA [25] . Fatigue is not often investigated as a predictor of functional outcome, but has been inversely associated with remission in RA [26] . This work has supported previously noted associations of female gender and obesity with poor outcome and highlighted an under-reported association of baseline fatigue with adverse outcome. It was not possible to assess the effect of socio-economic status on outcome in IACON, because the data were not available to the study team.
Therefore, this may be an unmeasured confounder and could have influenced the finding of an association of poor outcome with higher baseline BMI and fatigue.
However, we obtained data on area-level social deprivation for YEAR, and a posthoc analysis (results available in online supplementary Table 11 ) found that female gender, BMI, fatigue and social deprivation were all independent predictors of high stable, compared to low reducing HAQ trajectory in YEAR.
As this study used data from two early RA cohorts, in which standard care was The follow up duration for this study was 2 years, which may explain why the present analysis revealed only 2 trajectories of HAQ, compared to 4 in the Early RA Study (ERAS) and Norfolk Arthritis Register (NOAR) [19, 28] , both of which used data from patients followed for substantially longer durations. The results presented here also differed from those of a previous report of trajectories of change in DAS28, where 3 trajectories over 12 months were identified [29] . One possible explanation is that the fit of our initial model was superior to the previously published work in which trajectories of DAS28 were described within quadratic growth curve models.
Quadratic models assume a quadratic (curve shaped) change over time, whereas freed loading growth curve models [30] were applied to the YEAR and IACON data, which allowed the growth curve to take any shape and resulted in very good fit of our data to the initial model. Fit of the growth curve models is described in online supplementary Table 6 .
In summary, the findings from this work were consistent with the wealth of evidence supporting T2T approaches for the suppression of disease activity in early RA.
Although there was some improvement in HAQ in the T2T group compared to the group treated with 'step-up' therapy, most cases followed a 'moderate' HAQ trajectory, in which there was significant functional impairment throughout follow-up.
Women, older people, those with higher BMI, and those reporting greater fatigue at baseline were more likely to fall into this group, suggesting that such patients may benefit from therapies targeted at improving function in addition to those targeted at suppression of inflammation. *Rheumatoid factor positivity was considered in separate models and the results did not change significantly.
TABLES
Figure 1. Cases from YEAR and IACON cohorts included in analysis.
DAS28, disease activity score from counts of 28 joints; IACON, Inflammatory Arthritis Continuum; RA, rheumatoid arthritis; YEAR, Yorkshire Early Arthritis Register 
